A Phase 2, 12-Week, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of J867 [asoprisnil] on Uterine Artery Blood Flow and the Morphology of the Endometrium, Myometrium, and Uterine Leiomyomata in Subjects With Uterine Leiomyomata Scheduled for Hysterectomy.

Trial Profile

A Phase 2, 12-Week, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Effects of J867 [asoprisnil] on Uterine Artery Blood Flow and the Morphology of the Endometrium, Myometrium, and Uterine Leiomyomata in Subjects With Uterine Leiomyomata Scheduled for Hysterectomy.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2008

At a glance

  • Drugs Asoprisnil (Primary)
  • Indications Uterine leiomyoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Dec 2008 Results have been published in the Journal of Clinical Endocrinological Metabolism.
    • 27 May 2008 Trial sponsor and affiliate changed from TAP Pharmaceutical Products to Abbott Laboratories. Updated from ClinicalTrials.gov.
    • 12 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top